Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older

PHASE1,PHASE2

Phase

COMPLETED

Status

440

Enrollment

OTHER

Sponsor class

Conditions

BIOLOGICAL: the vaccine with high doses of virus content between 4.7～5.0 lgPFU
BIOLOGICAL: the vaccine with low doses of virus content between 4.7～5.0 lgPFU
BIOLOGICAL: the vaccine with high doses of virus content between 4.3～5.0 lgPFU
BIOLOGICAL: the vaccine with middle doses of virus content between 4.3～5.0 lgPFU
BIOLOGICAL: the vaccine with low doses of virus content between 4.3～5.0 lgPFU
BIOLOGICAL: placebo

Beijing Chaoyang District Centre for Disease Control and Prevention